Stocks Health care PHAT
NASDAQ · Health carePhathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. brought in $239.7M of revenue over the twelve months to June 30, 2026, up 110.2% from a year earlier. It posted a net loss of $99.1M. In fiscal 2025 capital spending exceeded operating cash flow by $167M. At June 30, 2026 it held $182.5M in cash against $164.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 30, 2026.
What Phathom Pharmaceuticals, Inc. does
Phathom Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PHAT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $175.1M | -$221.2M | -$3.03 | -$167M |
| 2024 | $55.3M | -$334.3M | -$5.29 | -$266.9M |
| 2023 | $682K | -$201.6M | -$3.93 | -$139.2M |
| 2022 | $0 | -$197.7M | -$5.05 | -$147.6M |
| 2021 | n/a | -$143.9M | -$3.89 | -$148.8M |
| 2020 | n/a | -$129.1M | -$3.88 | -$70.7M |
Where PHAT ranks in Health care
Latest SEC filings
What Phathom Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026
- July 30, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 20, 2026Passive stake changed SCHEDULE 13G/A
- June 23, 2026Other event 8-K
- May 21, 2026
- April 30, 2026Quarterly report 10-Q · period to March 31, 2026
- April 30, 2026
- April 7, 2026Additional proxy material DEFA14A
- April 7, 2026
Insider trades
What the people running Phathom Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 3, 2026 | Breedlove Robert CharlesPrincipal Accounting Officer | Shares withheld for tax | 460 | $4.2K |
Questions about PHAT
What does Phathom Pharmaceuticals, Inc. do?
Phathom Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PHAT.
Is Phathom Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $99.1M on revenue of $239.7M.
How much revenue does Phathom Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Phathom Pharmaceuticals, Inc. reported revenue of $239.7M. That is 110.2% more than a year earlier.
When did Phathom Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 30, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 8, 2026.
Similar companies
Compare PHAT with
Follow PHAT
Get an email when Phathom Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PHAT: get an email when it filesWhere the numbers come from
Financial figures are the values Phathom Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.